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Na+-glucose cotransporter 2 is the renal Na+-coupled glucose transporter
responsible for the tubular glucose reabsorption, while MAP17 was recently
identified as its accessory unit. Mutations in either of the proteins’ coding
genes, SLC5A2 and PDZK1IP1, lead to urinary glucose excretion. To inves-
tigate whether MAP17 interacts with SGLT2 in vitro, we engineered a V5-
tagged SGLT2 construct and evaluated HEK293T cells coexpressing it
together with a HA tagged MAP17 construct. MAP17 is shown to colocalize
and coimmunoprecipitate with SGLT2. Also, in human kidney sections, the
expression of both proteins overlaps at the apical surface of tubular epithelia.
This interaction provides the rationale behind SGLT2 activation by MAP17
as well the similarity of the SLC5A2 and PDZK1IP1 glucosuric phenotypes.
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Two distinct members of the Na+-coupled glucose
transmembrane transporter family, SGLT1 and
SGLT2, are responsible for the uptake of glucose from
the proximal tubular lumen, the latter accounting for
97% of the glucose transport. Mutations in the
SGLT2 coding gene, SLC5A2, cause familial renal glu-
cosuria (FRG) [OMIM 233100], a codominant inher-
ited phenotype characterized by the presence of
glucosuria in the absence of generalized proximal
tubule dysfunction or hyperglycemia [1].
The identification of SGLT1 [2] enabled the cloning
of SGLT2 from a similar human kidney cDNA [3] that
displayed distinct molecular and electrophysiological
properties [4]. Selected as a candidate gene, SLC5A2
was later found to underlie FRG [5].
Functionally, and compared to SGLT1, SGLT2
expresses poorly in transfected mammalian cells or
Xenopus laevis oocytes and this fact has hampered a
detailed characterization of its transport kinetics. Such
a limitation was only circumvented by whole-cell
patch-clamp techniques that have enabled the electro-
physiological assessment of SGLT2 glucose transport
[6]. Recently, MAP17 was identified by expression
cloning as a SGLT2 b-subunit, while homozygous
Abbreviations
FRG, Familial Renal Glucosuria; HEK293T, human embryonic kidney cells; MAP17, 17 kDa membrane-associated protein; MDCK, Madin–Darby
canine kidney cells; NHERF3, NHE3 regulatory factor 3; OK, opossum kidney cells; PDZK1IP1, PDZK1-interacting protein 1 (MAP17-coding
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SLC5A2, the SGLT2 solute carrier coding gene.
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mutations in PDZK1IP1 (MAP17 encoding gene) were
found in one FRG individual negative for SLC5A2
mutations [7]. In both mammalian cells [7] and oocytes
[7,8], coexpression of MAP17 greatly increased SGLT2
transport activity and a comprehensive evaluation of
SGLT2/MAP17 complex transport kinetics was
achieved. It was found that glucose affinity for
SGLT2, with a reported Km of 3.4 mM, is ~10x lesser
when compared to SGLT1 [8]. These findings validated
earlier brush border membrane vesicle studies and
microperfusion experiments (reviewed in [9]) as well
observations in the Sglt2-deficient mice [10], that pre-
dicted an active glucose transport in the early S1 prox-
imal tubule via a low-affinity/high-capacity transporter
(SGLT2/MAP17), while in the later S3 segment, a
high-affinity/low-capacity system would predominate
(SGLT1). Therefore, the differences in expression pat-
terns and transport kinetics of both systems along the
proximal tubule act in synergy to minimize glucose
loss in the urine.
The way MAP17 and SGLT2 interact is not clear.
Immunofluorescence and Western experiments with
OK cells cotransfected with tagged constructs for both
proteins, did not reveal an increase in SGLT2 cell sur-
face expression [7]. This lead the authors to hypothe-
size that MAP17 could induce a SGLT2
conformational change, responsible for the observed
cotransporter increased activity.
However, an interaction between both proteins has
never been explored. In order to do so, we have
used two different cellular models expressing SGLT2
and MAP17 constructs, tagged with, respectively, V5
and HA epitopes, and assessed their interaction
in vitro by immunofluorescence and immunochemistry
techniques using anti-V5 and -HA antibodies. We
first engineered a V5-tagged SGLT2 construct and
produced a cell line that stably expressed the con-
struct, with the purpose of minimizing cellular pro-
tein overloading in colocalization studies and, hence,
reproduce a more physiological level of protein
abundance. This cell line was subsequently tran-
siently transfected with the HA-tagged MAP17 con-
struct, and subcellular localization of both proteins
was assessed by confocal microscopy. Also,
HEK293T wild-type cells were cotransfected with
both tagged constructs, aiming at a transient overex-
pression of both proteins, and were evaluated by
immunocytochemistry as well as coimmunoprecipita-
tion assays. Additionally, we performed immunofluo-
rescence labeling of MAP17 and SGLT2 in
paraffin-embebbed kidney biopsies with no detectable
histopathological changes with antipeptide antibodies
for MAP17 and SGLT2.
Materials and methods
Plasmid construction
We purchased the human SGLT2 cDNA cloned in a pEZ-
M29 plasmid displaying an EGFP N-terminal tag (Geneco-
poeia, clone EX-C0047-M29) and subsequently sequenced
it with internal primers in order to verify the identity with
Genebank accession NM_003041. The SGLT2 cDNA insert
was long-range PCR amplified with the following sense,
ATTGAATTCAACCATGGAGGAGCA, and reverse,
TATAAGCTTAGGCATAGAAGCCCC, primers that
introduced new restriction sites, and then ligated to an
empty pcDNA3.1 plasmid after double EcoRI/HindIII
digestion of, both, the insert and vector, originating the
pcDNA3.1 SGLT2. The insert was again sequence verified
and directly cloned into the pcDNA ENTR BP V5 by
digesting the insert with EcoRI/PmeI and the vector with
EcoRI/EcoRV. The pcDNA ENTR BP V5 had been previ-
ously generated based on the pcDNA ENTR BP GFP [11],
a mammalian expression Gateway plasmid (Invitrogen,
Carlsbad, CA, USA), by swapping the GFP with the V5 epi-
tope and a chemically synthesized polylinker. The V5 epitope
and the polylinker were digested with NheI/BamHI and
cloned in the vector previously digested with the same set of
restriction enzymes. This pcDNA ENTR BP V5-SGLT2 con-
struct has, therefore, an engineered N-terminal V5 and was
created with the ultimate goal of mammalian cell line trans-
duction using a pLenti6-DEST gateway vector expression sys-
tem. The pcDNA ENTR BP V5-SGLT2 was also sequence
verified before heterologous expression studies.
The plasmid containing the human MAP17 with a HA
epitope inserted at residue 23, referred as pcDNA3.1
HA23MAP17, was a kind gift from M. Coady (Montreal,
CA, USA).
Cell culture, transient transfection, and stable
cell line production
The HEK293T cells were grown in DMEM medium
(Gibco, Carlsbad, CA, USA) supplemented with 10% heat-
inactivated FBS and 5% penicillin–streptomycin antibiotic
solution. For stable cell line production, HEK293T cells
were transfected with pLenti V5-SGLT2 plasmid using Jet-
prime DNA-siRNA transfection reagent (Polyplus, Illkirch,
France). Lentiviral particles were collected after 4 days and
stored at 80 °C. These were used to transduce HEK293T
cells for 24–48 h; cells were then positively selected for
1 week with 8 lgmL1 blasticidine (Invitrogen), followed
by clone selection. This cell line will be referred throughout
the text as HEK293T V5-SGLT2.
For immunofluorescence experiments, cells were seeded
on glass coverslips in 12-well plates and either cotransfected
(for HEK293T wild-type) with a total of 400 gg of pcDNA
ENTR BP V5-SGLT2 and pcDNA3.1 HA23MAP17 DNA,
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or transfected (for HEK293T V5-SGLT2) with 200 gg of
the latter, using the Jetprime DNA-siRNA transfection
reagent. For western blot or coimmunoprecipitation, 60-
mm Petri dishes and 2 lg of DNA were used instead. Cells
were transfected at 40–50% confluence and then harvested
for various analyses at 24–48 h post transfection.
In order to validate heterologous expression of single
transfection experiments and evaluate anti-SGLT2 and -
MAP 17 antibodies specificity, we compared nontransfected
and single transfection experiments with either pcDNA
ENTR BP V5-SGLT2 or pcDNA3.1 HA23MAP17, this
time using 200 gg and 1 lg of DNA for immunofluores-
cence experiments and western blot analysis, respectively.
Immunofluorescence analysis of cell lines
Transfected HEK293T or HEK293T V5-SGLT2 cells were
grown on glass coverslips for 24–48 h after transfection,
then washed with PBS and fixed in 4% formaldehyde in
PBS at room temperature (RT) for 10 min, washed again
and permeabilized with a solution of Triton X-100 0.25%
in PBS for 10 min at RT. Samples were blocked with 3%
BSA in PBS for 30 min at RT, then incubated with rabbit
anti-HA rhodamine TRITC conjugate antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA #sc-805) at
1 : 20 dilution in 1% BSA in PBS for 2 h at RT, after
which they were washed and incubated overnight at 4 °C
with a goat anti-V5 epitope primary antibody (Sicgene,
Coimbra, Portugal #AB0096-500) at 1 : 1000 dilution in
1% BSA in PBS. The following day, cells were incubated
with donkey anti-goat IgG Alexa Fluor 488 secondary anti-
body (Thermo Fisher Scientific, Waltham, MA, USA #A-
11055) for 45 min at RT, 1 : 800 dilution in 1% BSA in
PBS. After additional washing, cells were incubated for
8 min at RT with a Hoechst (Chemicon International,
Temecula, CA, USA) solution of 0.25 lgmL1 in water
and finally mounted in Vectashield (Vector Laboratories,
Burlingame, CA, USA). Immunolabeling was evaluated
with a confocal LSM710 microscope using the ZEN software
(all Carl Zeiss GmbH, Darmstadt, Germany).
In single-transfection experiments, for assessing heterolo-
gous expression of cellular systems and anti-SGLT2 or -
MAP17 antibody specificities, similar protocols were used.
However, additional goat primary antibodies against peptides
from the human proteins SGLT2 (Santa Cruz Biotechnology
#sc-47402) and MAP17 (Santa Cruz Biotechnology #sc-
27376) were used, both at 1 : 60 dilution.
Western blot analysis of cell lysates
Whole-cell lysates were recovered from 60-mm Petri dish
samples by adding 300 lL of 1X Laemmil reducing buffer,
followed by continuous gentle agitation for 10 min on ice,
and, once recovered in a 2-mL polypropylene tube, submit-
ted to brief sonication. For SGLT2 immunodetection, 10–
20 lL of protein extracts were immediately separated by
SDS/PAGE electrophoresis in a 10% acrylamide gel and
transferred onto nitrocellulose membranes at 75 V constant
for 90 min, while for MAP17, samples were heated to
95 °C for 10 min previous to SDS/PAGE electrophoresis in
a 12.5% gel and further transferred onto nitrocellulose
membranes at 75 V constant for 45 min.
Membranes were incubated for 1 h at RT in blocking buf-
fer (2% egg albumin in PBS-Tween 0.01%), washed twice in
PBS-Tween 0.01% and incubated at 4 °C overnight in
PBS-Tween 0.01% with the following primary goat antibodies
(and dilutions): anti-V5 (1 : 2500), anti-HA (1 : 1000), anti-
SGLT2 (1 : 500), and anti-MAP17 (1 : 500). For western blot
analysis of coimmunoprecipitation beads’ elution, mouse anti-
V5 (Invitrogen #46-0705; 1 : 2000) and mouse anti-HA
(Thermo Fisher Scientific #26183; 1 : 500) primary antibodies
were used instead of goat antibodies. After washing with
PBS-Tween 0.01%, the membranes were incubated for
45 min at RT with horseradish-coupled secondary antibodies
against goat (Thermo Fisher Scientific #A2446) or mouse
(Invitrogen #67-652) IgG in 1% egg albumin blocking solu-
tion. The western blot was developed using a chemilumines-
cent detection reagent (GE Healthcare, Chicago, IL, USA)
and image acquisition performed in a ChemiDoc Touch
Image system and analyzed using the IMAGE LAB 5.2 software
(all Bio-Rad, Hercules, CA, USA).
Coimmunoprecipitation
Cell lysates were prepared using a mixture of 2% of
CHAPS (BioChemica, Darmstadt, Germany), NP-40 (Cal-
biochem, La Jolla, CA, USA), and Triton X-100 (Sigma,
St. Louis, MO, USA) in lysis buffer (150 mM NaCl and
50 mM Tris-HCl pH 7.4), since SGLT2, a predicted 14
transmembrane domain protein, was found difficult to elute
from membrane fractions if only 1% CHAPS was being
used. This was the reason, too, on why we were not able to
recover enough SGLT2 in the lysate supernatant from the
HEK293T V5-SGLT2 cell line and, therefore, restricted our
coimmunoprecipitation experiments to cotransfected cells
overexpressing the SGLT2 construct.
Protein lysates were recovered from transfected
(pcDNA3.1 HA23MAP17 for HEK293T V5-SGLT2) and
cotransfected (pcDNA ENTR BP V5-SGLT2 and
pcDNA3.1 HA23MAP17 for HEK293T wild-type) cells
grown in 60-mm Petri dishes, by incubating the samples
with 300 lL of 2% lysis buffer supplemented with an in-
house prepared protease inhibitor cocktail, under gentle
agitation for 10 min on ice. Once transferred to a 2-mL
polypropylene tube, samples were further incubated on ice
for 2 h while being vortexed and homogenized every
15 min and, finally, centrifuged 17 000 g for 20 min at
4 °C. V5-SGLT2 immunoprecipitation was performed by
incubating overnight, at 4 °C, the lysate supernatant with
20 lg of goat anti-V5 antibody in a 0.5% lysis buffer, and,
in the following night, with protein G sepharose beads
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(Invitrogen). The beads were then rinsed three times with
lysis buffer and proteins eluted in 70 lL of 1X Laemmil
loading buffer, heated to 50 °C for 10 min. Subsequently,
samples were processed for immunoblotting. Findings were
replicated in two independent experiments.
Western blotting, histological examination, and
immunofluorescence of kidney specimen
Membrane protein fractions from surgical biopsy samples
of nontumor-involved areas of nephrectomy specimen were
recovered using the ProteoJET protein extraction kit
(Thermo Fisher Scentific) according to manufacturer’s
instructions and frozen at 80 °C until further analysis.
Twenty micrograms of protein was applied in each lane
and immunoblotted with goat primary antipeptide antibod-
ies against human SGLT2 and MAP17 as detailed above.
For immunofluorescence purposes, formalin-fixed and
paraffin-embedded kidney biopsies showing no detectable
histopathological changes were evaluated. Heat-induced
epitope retrieval was applied to 3-lm consecutive sections
of the specimen with Target Retrieval Solution pH 9
(Dako, Santa Clara, CA, USA) at 95–99 °C for 20 min.
Incubations with goat primary antibodies anti-human
MAP17, at 1 : 20 dilution, and anti-human SGLT2, at
1 : 5 dilution, as well donkey anti-(goat IgG) Alexa Fluor
488 secondary antibody, at 1 : 200 dilution, were all carried
out for 1 h at RT. An epifluorescence Zeiss Axio Imager
Z2 microscope was used for image acquisition and analysis,
using the ZEN software. And since both primary antibodies
originated from goat, colocalization experiments were not
carried out. Instead, we used topology references across
sections to evaluate the extension of overlap in proteins’
expression.
Results
Western blotting of whole-cell lysates from
transfection experiments
To confirm that SGLT2- and MAP17-tagged proteins
were being properly expressed with the expected molecu-
lar weight in our cellular models and, simultaneously, to
evaluate primary antibody specificity against tags (V5,
HA) or the human proteins (SGLT2, MAP17), we stud-
ied HEK293T cells transfected with the different plasmid
constructs by immunofluorescence (Fig. S1) and western
blotting of whole-cell lysates (Fig. 1). For the pcDNA
ENTR BP V5-SGLT2 plasmid construct, both anti-
SGLT2 (Fig. 1A lane 3) and anti-V5 (Fig. 1A lane 6)
antibodies identified a broad band of 65 kDa in samples
from transfected cells and that was slightly larger than
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Fig. 1. Western blot analysis of heterologous expression of SGLT2 and MAP17 constructs in HEK293T cells. (A) Western blot of SGLT2
constructs: immunoblotting of samples transfected with the V5 construct, using either anti-SGLT2 (lane 3) or anti-V5 (lane 6) antibodies,
revealed a broad band of ~65 kDa that is slightly larger than the one observed for the untagged protein (lane 4) probed with anti-SGLT2
antibody. In HEK293T transduced with the lentivirus expressing the V5-SGLT2 construct, a similar band is observed, either with anti-SGLT2
(lane 1) or anti-V5 (lane 5). (B) Western blot of the HA23MAP17 construct reveals the same ~15 kDa band when immunoblotted with either
anti-MAP17 (lane 2) or anti-HA (lane 3) antibodies. V5-SGLT2 transd: HEK293T transduced with the lentivirus expressing V5-SGLT2
construct; V5-SGLT2 transf: HEK293T-transfected with the V5-SGLT2 construct; SGLT2 transf: HEK293T transfected with the untagged
SGLT2 construct; HA23MAP17 transf: HEK293T transfected with the HA23MAP17 construct; ctrl: nontransfected HEK293T wild-type cells
used as controls.
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SGLT2 and immunoblotted with the anti-SGLT2 anti-
body (Fig. 1A lane 4). This finding is in accordance with
the V5 N-terminal modification of SGLT2 in the
pcDNA ENTR BP V5-SGLT2 construct. In the
HEK293T V5-SGLT2 cell line that stably expressed the
V5-SGLT2 construct, a band of similar molecular weight
was also detected with anti-SGLT2 (Fig. 1A lane 1) or
anti-V5 (Fig. 1A lane 5) antibodies, although, for the lat-
ter, an additional and close together smaller band, was
also observed. For the transfection experiments with
pcDNA3.1 HA23MAP17 plasmid, immunoblotting with
either anti-MAP17 or anti-HA, gave rise to a similar
band of 15 kDa in transfected cells (Fig. 1B, lanes 2 and
3). Therefore, we confirmed that the engineered con-
structs lead to mammalian cell expression of SGLT2 or
MAP17 at the expected molecular weight and that anti-
bodies against V5 or HA tag epitopes and SGLT2 or
MAP17 are similarly specific in these whole cell lysates
from heterologous expression experiments.
MAP17 colocalizes with SGLT2
To initially test the hypothesis that MAP17 and
SGLT2 interact, we cotransfected HEK293T with the
tagged SGLT2 and MAP17 constructs and evaluate
their subcellular localization. Similar assays were per-
formed with the HEK293T V5-SGLT2 cell line stably
expressing the V5-SGLT2 construct and transfected
with pcDNA3.1 HA23MAP17 plasmid. By confocal
microscopy, and after dual immunolabeling, MAP17
was shown to colocalize with SGLT2 in both
HEK293T cell lines (Fig. 2). In addition to a very
strong perinuclear staining, the observed vesicular pat-
tern is compatible with the localization of proteins
within lipid rafts. HEK293T are not polarizable cells
and so, a clear membrane cell surface expression is not
expected to occur.
MAP17 coimmunoprecipitates with SGLT2
The colocalization of both proteins provided the first
clue that MAP17 and SGLT2 could interact physically.
To further explore the in vitro interaction of both pro-
teins, coimmunoprecipitation experiments were per-
formed (Fig. 3). HEK293T cells were either transfected
with pcDNA3.1 HA23MAP17 alone, or cotransfected
with pcDNA3.1 HA23MAP17 and pcDNA ENTR BP
V5-SGLT2 plasmids. Coimmunoprecipitation of
V5-SGLT2 HA23MAP17merge
Fig. 2. Confocal immunofluorescence imaging of representative X-Y planes of heterologous cellular systems expressing SGLT2 and MAP17
constructs. Top panel: cotransfected cells with the V5-tagged SGLT2 and the HA-tagged MAP17 constructs. Lower panel: HEK293T
transduced with lentivirus expressing the V5-tagged SGLT2 construct that were transfected with the HA-tagged MAP17 coding plasmid.
MAP17 is seen to colocalize with SGLT2 (arrows) in intense perinuclear and vesicular patterns. Incubation was performed with rabbit anti-
rhodamine TRITC conjugate antibody followed by goat anti-V5 primary and donkey anti-goat IgG Alexa Fluor 488 secondary antibodies, as
described in material and methods. Nuclear DNA stained by Hoechst. Scale bar, 5 lm.
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V5-tagged SGLT2 was performed with goat anti-V5
antibody in the presence of protein G sepharose beads.
Western blot analysis of eluted proteins with mouse
anti-V5 and HA immunoblotting identified the HA-
tagged MAP17 construct in eluted proteins originating
from lysate supernatant of cotransfected samples, but
not when MAP17 was being overexpressed alone, pro-
viding evidence that SGLT2 and MAP17 do interact
with each other in vitro.
MAP17 and SGLT2 overlap their expression in
human normal kidney
We extended our observations to normal human kid-
ney biopsies and assessed the expression of both pro-
teins. Specificity of the antipeptide human SGLT2 and
MAP17 antibodies was assessed by western blotting
(Fig. 1) or immunocytochemistry (Fig. S1) analysis of
HEK293T transfected and transduced with the differ-
ent cDNA constructs. In addition, western blotting of
protein membrane fractions of normal human kidney
incubated with the anti-human SGLT2 and MAP17
antibodies, revealed the expected bands of 75 and
17 kDa, respectively (Fig. 4). For SGLT2, a less
intense band of an estimated molecular weight of
135 kDa was also identified, probably resulting from
SGLT multimerization reported to occur when frozen
samples are used [9]. The western blot analysis of
SGLT2 in human kidney now presented, replicate our
previous findings that have been published in the
abstract form (Aires I, Santos AR, Genc G, Bogarin
R, Calado JT. Glucose transport in the proximal
tubule: disruption of urate transport in familial renal
glucosuria and report on SGLT2 expression in normal
and pathological kidney [Abstract] (2012) J Am Soc
Nephrol 23, 730A). Finally, in the formalin-fixed and
paraffin-embedded specimen, we found that SGLT2
and MAP17 largely overlap their expression (Fig. 4).
Specifically, both displayed similar topological expres-
sion at the brush border of proximal tubule epithelial
cells.
Discussion
Na+-glucose cotransporter 2 is a predicted 14 trans-
membrane domain Na+-coupled glucose transporter
that accounts for the bulk of glucose reabsorption in
the proximal tubule and, as such, mutations in its cod-
ing gene are responsible for the large majority of FRG
cases [5]. Recently, SGLT2 was selected as a therapeu-
tic target for the treatment of type 2 diabetes mellitus
based on the rational that SGLT2 pharmacological
inhibition would lead to a significant reduction in the
renal threshold for glucose excretion and, therefore,
promote urinary disposal of the excess of glucose [12].
In spite of the fact that hundreds of thousands of dia-
betic individuals are currently taking SGLT2 inhibitors,
little is known about SGLT2 post-transcriptional regu-
lation. The finding, by means of expression cloning,
that MAP17 is an accessory unit for the activity of
SGLT2 provided the first hint on such a regulation [7].
MAP17, a two-transmembrane protein, was first
cloned by differential display techniques as a protein
upregulated in several human carcinomas [13]. In nor-
mal tissues, however, it is only significantly expressed
in the human kidney, where it locates to the brush
border of proximal tubular cells [13]. Further insights
on the role of MAP17 in the proximal tubule were
revealed by two-hybrid experiments that have used
PDZ domains from the PDZK1 protein as baits for an
adult mouse kidney cDNA library, and through which









Fig. 3. In vitro interaction between SGLT2
and MAP17. HA23MAP17 is present in
lysates (input) of cells transfected with
pcDNA3.1 HA23MAP17 or cotransfected
with pcDNA ENTR BP V5-SGLT2 and
pcDNA3.1 HA23MAP17. However, only in
the presence of V5-SGLT2 was
HA23MAP17 coimmunoprecipitated by
goat anti-V5 antibody, as detected in the
output using mouse anti-HA antibody. WB,
western blot; IP, immunoprecipitate.
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interact with PDZK1 [14]. PDZK1 (now renamed
NHERF3), a member of a large family of PDZ pro-
teins, is the major scaffolder in the brush border, coor-
dinating the abundance of transport and signaling
proteins like NaPi-IIa, NH3, CFEX, URAT1, or
PTHR1, all displaying a COOH-terminus PDZ recog-
nition consensus sequence [14]. Additionally, the NH2
terminus of NaPi-IIa interacts with MAP17 and both
proteins are expressed within the S1 segment of the
proximal tubule while overlapping in their localization
to the brush border [15]. It was also shown that the
coexpression of MAP17 and PDZK1 induced internal-
ization of NaPi-IIa, therefore postulating a role for the
heterotrimeric complex in phosphate reabsorption [16].
In a similar manner, our current work aimed at pro-
viding evidence that MAP17 interaction with SGLT2
underlies the reported increased transport activity of
the SGLT2/MAP17 complex. We designed two
heterologous cellular expression models to test for an
in vitro interaction: one, based on a lentivirus-trans-
duced V5-tagged SGLT2 construct that we have engi-
neered, followed by transfection with the HA-tagged
MAP17 construct; the other, on the simultaneous
cotransfection of both constructs. The major advan-
tage of the former model is to minimize SGLT2 pro-
tein cell overloading that could limit the interpretation
of colocalization studies. Due to the uncertainty
regarding the specificity of the commercially available
antipeptide antibodies against SGLT2 or MAP17,
anti-V5 and -HA epitopes antibodies were used,
instead, as reference. The expected molecular weight
for SGLT2 is 70–75 kDa which has been verified in
several reports using kidney tissue [9,10,17] although it
can vary with the degree of glycosylation, depending
on the species or cell type [9]. Western blotting of



















Fig. 4. Constitutive SGLT2 and MAP17 expression in the human kidney. Consecutive kidney sections immunolabeled with goat anti-MAP17
(top panel) or SGLT2 (bottom panel) antibodies are shown. For each antibody, the immunoblotting of protein extracts from human normal
kidney is also depicted. In two distinct areas of the cortex (A and B), both proteins are shown to largely overlap their expression in the
apical surface of epithelial cells of proximal tubules. For each area, the same specific arrow (of a given size and direction) is used to point
out, across sections, the tubule segments simultaneously expressing MAP17 and SGLT2. Donkey anti-(goat IgG) Alexa Fluor 488 was used
as a secondary antibody, as described in material and methods. Glm, glomerulus; scale bar, 20 lm.
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against SGLT2 used in the current study revealed a
band of 75 kDa. But our SGLT2 constructs, when
overexpressed in HEK293T cells, displayed a molecu-
lar weight 65 kDa, regardless of whether we were
using antibodies against V5 or SGLT2. The difference
in the observed molecular weight may be caused by
incomplete denaturation of multiple-pass transmem-
brane proteins by SDS [9] and has been reported
already in a HA-tagged SGLT2 construct also overex-
pressed in HEK293T cells and blotted with an anti-
HA antibody [18]. In our experiments, SGLT2
immunoblotting was performed immediately after
recovery of cell lysates and using nonheated samples,
since, similarly to what was described for other trans-
membrane proteins [19], denaturation greatly impaired
SGLT2 immunodetection. This fact, coupled with the
complexity of membrane protein glycosylation seen in
whole-cell lysates, is responsible for the multiple band
pattern observed in transfected cells. However, it can-
not account for the discrepancy observed between
transduced cells immunoblotted with anti-SGLT2
(Fig. 1A lane 1) and anti-V5 (Fig. 1A lane 5) antibod-
ies, displaying, respectively, one or two closely located
bands. We can presume that some degree of prote-
olytic degradation may have occurred, affecting the
epitope recognized by the anti-SGLT2 antibody.
Accordingly, anti-V5 (at the NH2 terminus of the con-
struct) recognizes the full length as well the partially
degraded protein, while the anti-SGLT2 only identifies
the nondegraded form. In transfected cells this may
have been unnoticed due to the higher level of protein
expression.
In both HEK293T cell lines (wild-type and V5-
SGLT2), heterologous expression revealed that
MAP17 colocalizes with SGLT2 in a perinuclear and
vesicular pattern. HEK293T are not polarizable cells
and so, the lack of clear surface expression was not
unexpected. Previous work on similarly transfected
HEK293T cells detailing the kinetics of glucose trans-
port and using radiotracer uptake and patch-clamp
techniques, provides strong evidence that in HEK293T
overexpressing SGLT2, an adequate amount of the
transporter is inserted in the membrane of these cells
[6]. It is unfortunate that, in spite our best efforts, we
did not succeed in developing in the more suitable OK
or MDCK cell lines, a clone stably expressing the V5-
tagged SGLT2 protein. In line with the colocalization
experiments, our coimmunoprecipitation assays using
the HEK293T cell line cotransfected with the SGLT2-
and MAP17-tagged constructs, revealed that MAP17
coimmunoprecipitated with anti-V5 antibodies, only if
the V5-tagged SGLT2 construct was simultaneously
being overexpressed. These findings further strengthen
the hypothesis that, at least in these cellular models,
both proteins interact. Still, the approach used in the
current work cannot unravel the nature of this interac-
tion. Namely, we cannot confirm if MAP17 is a direct
binding partner of SGLT2 or, alternatively, this inter-
action is mediated by additional proteins constitutively
expressed in HEK293T cells, nor can we identify the
protein domains involved.
Contrary to PDZ-interacting proteins like NaPi-IIa,
SGLT2 displays no COOH-terminus PDZ recognition
consensus sequence and accordingly, transport activity
of the SGLT2/MAP17 complex was not impaired
when SGLT2 was coexpressed with a MAP17 con-
struct lacking the terminal PDZ recognition consensus
sequence STPM (MAP17DSTPM) instead of the full-
length protein, revealing that the heteromeric complex
is fully functional in the absence of PDZK1 [7]. Also,
the Pdzk1 knockout mouse has been published and
while urinary glucose excretion was not specifically
evaluated, compared to wild type, there was no differ-
ence in plasma glucose concentration [20]. NaPi-IIa/
MAP17 interaction was identified by two-hybrid exper-
iments but never confirmed by the in vitro interaction
assays performed, leading to the conclusion that this
was an interaction of a weak nature that could only be
stabilized within the MAP17/NaPi-IIa/PDZK1 com-
plex [15]. Our coimmunoprecipitation results postulate,
instead, a strong interaction between SGLT2 and
MAP17, a fact that could obviate PDZK1 stabiliza-
tion, in agreement with the above-mentioned transport
experiments performed with SGLT2/MAP17DSTPM.
Finally, we have shown that SGLT2 and MAP17
overlap their expression at the apical surface of proxi-
mal tubule epithelial cells in the human kidney. Previ-
ous reports have documented, separately, for SGLT2
[21] or MAP17 [13], that these proteins are expressed
at the brush border of the proximal tubule epithelial
cells of the human kidney. We now provide evidence
that their expression overlaps along similar segments
of the proximal tubule. Having performed the
immunofluorescence staining of human kidney sections
with available commercial antibodies, and aware that,
for SGLT2 in particular, there are few well-character-
ized antibodies [17,22,23], we validated the purchased
anti-SGLT2 and -MAP17 antibodies in heterologous
expression systems, by crosschecking them with the
anti-tag antibodies used as reference, and also by
immunoblotting with protein extracts from normal
human kidney.
In summary, we here provide evidence that SGLT2
and MAP17 when overexpressed interact in vitro and,
likewise, under constitutive expression in the kidney
they also overlap their expression in the proximal
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tubule. This interaction may provide the rationale
behind the SGLT2-mediated glucose transport activa-
tion by MAP17 as well the similarity of the SLC5A2
and PDZK1IP1 glucosuric phenotypes.
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